Schlemm canal stenting

Summary In primary open‐angle glaucoma, the juxtacanalicular trabecular meshwork and inner wall of Schlemm canal are believed to be the site of greatest resistance to aqueous outflow. Recently several new minimally invasive devices have been developed to bypass this tissue and provide direct access to low resistance collector channels in the outer wall of Schlemm canal. These devices are inserted via an ab interno approach, usually at the time of cataract surgery, and are designed to lower intraocular pressure and reduce or eliminate the need for glaucoma medications. This Special Interest Symposium reviews the growing evidence base and covers techniques and pearls for the insertion of both the iS tent and iS tent Inject (Glaukos Corporation, Laguna Hills, CA, USA) as well as the Hydrus intracanalicular scaffold (Ivantis Inc., Irvine, CA, USA).